{"id":"psilocybin-usona-institute","safety":{"commonSideEffects":[{"rate":"null","effect":"Hallucinations"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL194378","moleculeType":"Small molecule","molecularWeight":"284.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This activation of the 5-HT2A receptor is thought to contribute to its therapeutic effects, although the exact mechanisms are not fully understood. Research suggests that psilocybin may facilitate changes in brain activity and connectivity, leading to improved mood and reduced symptoms of depression and anxiety.","oneSentence":"Psilocybin acts as a serotonin receptor agonist, specifically targeting the 5-HT2A receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:41.358Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Anxiety associated with life-threatening diseases"}]},"trialDetails":[{"nctId":"NCT07490353","phase":"PHASE1","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-11-01","conditions":"Depression - Major Depressive Disorder, Anhedonia","enrollment":85},{"nctId":"NCT07479550","phase":"PHASE2","title":"Anesthesia-Masked Psilocybin Therapy for Major Depression","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-07","conditions":"Major Depression","enrollment":10},{"nctId":"NCT07053917","phase":"PHASE1","title":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02-09","conditions":"Stroke, Chronic Stroke, Intracerebral Haemorrhage","enrollment":20},{"nctId":"NCT07406828","phase":"PHASE1","title":"Psilocybin After Trauma Surgery for Pain","status":"NOT_YET_RECRUITING","sponsor":"Trent Emerick","startDate":"2026-07","conditions":"Pain Management, Postoperative Pain","enrollment":70},{"nctId":"NCT07251491","phase":"PHASE1, PHASE2","title":"Psilocybin to Treat Depression in Spinal Cord Injury","status":"NOT_YET_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2026-01-01","conditions":"Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran","enrollment":30},{"nctId":"NCT06988319","phase":"PHASE1","title":"Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-01-01","conditions":"Chronic Pelvic Pain","enrollment":15},{"nctId":"NCT06512194","phase":"PHASE2","title":"Investigation to Understand and Optimize Psilocybin","status":"RECRUITING","sponsor":"Charles Raison","startDate":"2025-05-13","conditions":"Depression","enrollment":141},{"nctId":"NCT05163496","phase":"PHASE3","title":"Frontline Clinician Psilocybin Study","status":"COMPLETED","sponsor":"University of Washington","startDate":"2022-03-03","conditions":"Burnout, Caregiver, Burnout, Professional, COVID-19","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Magic Mushrooms","Psilocybin","Psychedelic-assisted psychotherapy (PAP)"],"phase":"phase_3","status":"active","brandName":"Psilocybin (Usona Institute)","genericName":"Psilocybin (Usona Institute)","companyName":"James J. Peters Veterans Affairs Medical Center","companyId":"james-j-peters-veterans-affairs-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Psilocybin acts as a serotonin receptor agonist, specifically targeting the 5-HT2A receptor. Used for Treatment-resistant depression, Anxiety associated with life-threatening diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}